Background: Episodic ataxia type 2 (EA2) is characterized by paroxysmal bouts of ataxia and progressive cerebellar dysfunction. Other manifestations may also be associated, such as migraine attacks with or without aura, absence epilepsy and mental retardation. Methods: To describe the intrafamilial variability of clinical manifestations of 3 patients harboring a novel CACNA1A point mutation in exon 7 (nucleotide insertion c.1063dupG) typical of EA2 mutation. Results: All 3 patients presented paroxysmal bouts of ataxia, but age of onset, associated symptoms and symptoms at clinical onset were clearly distinct with hemiplegic migraine attacks in the father, absence epilepsy in one child and mental retardation in the other child. Conclusion: Typical manifestations of EA2 may be associated and temporally preceded by rare manifestations such as hemiplegic migraine attacks, epilepsy and mental retardation. Moreover, patients sharing a given CACNA1A mutation may present very different phenotypes even within the same family.

Keywords:
Channelopathy, Migraine, Seizures, Vertigo, Episodic ataxia, Mental retardation
1.
Jen JC, Graves TD, Hess EJ, Hanna MG, Griggs RC, Baloh RW: Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain 2007;130:2484–2493.
2.
Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR: Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996;87:543–552.
3.
Ducros A, Denier C, Joutel A, Cecillon M, Lescoat C, Vahedi K, Darcel F, Vicaut E, Bousser MG, Tournier-Lasserve E: The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med 2001;345:17–24.
4.
Jen J, Kim GW, Baloh RW: Clinical spectrum of episodic ataxia type 2. Neurology 2004;62:17–22.
5.
Imbrici P, Jaffe SL, Eunson LH, Davies NP, Herd C, Robertson R, Kullmann DM, Hanna MG: Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia. Brain 2004;127:2682–2692.
6.
Jouvenceau A, Eunson LH, Spauschus A, Ramesh V, Zuberi SM, Kullmann DM, Hanna MG: Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet 2001;358:801–807.
7.
Guerin AA, Feigenbaum A, Donner EJ, Yoon G: Stepwise developmental regression associated with novel CACNA1A mutation. Pediatr Neurol 2008;39:363–364.
8.
Mochizuki Y, Kawata A, Mizutani T, Takamoto K, Hayashi H, Taki K, Morimatsu Y: Hereditary paroxysmal ataxia with mental retardation: a clinicopathological study in relation to episodic ataxia type 2. Acta Neuropathol 2004;108:345–349.
9.
Jen J, Yue Q, Nelson SF, Yu H, Litt M, Nutt J, Baloh RW: A novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia. Neurology 1999;53:34–37.
10.
Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T: Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 2004;62:1623–1625.
11.
Bertholon P, Chabrier S, Riant F, Tournier-Lasserve E, Peyron R: Episodic ataxia type 2: unusual aspects in clinical and genetic presentation: special emphasis in childhood. J Neurol Neurosurg Psychiatry 2009;80:1289–1292.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.